Поиск патентов

12-01-2012 дата публикации

Lactoferrin compositions and methods of wound treatment

Номер: US20120010150A1

Автор: Atul Varadhachary, Jose Engelmayer

Принадлежит: Agennix Inc

The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

Подробнее

Номер записи: 1

26-01-2012 дата публикации

Corrosion current-generating metal particulates and use thereof

Номер: US20120021014A1

Автор: Brooks Story, Chunlin Yang, James E. Hauschild, Jeannette Chantalat, Jeffrey C. Geesin, Jue-Chen Liu, Julia Hwang, Michael D. Southall, Wei Kong, William R. Parrish, Ying Sun

Принадлежит: Johnson and Johnson Consumer Companies LLC

Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.

Подробнее

Номер записи: 2

16-02-2012 дата публикации

Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Номер: US20120039980A1

Автор: David M. Gravett, George Y. Daniloff, Jacqueline Schroeder, Louis C. Sehl, Olof Mikael Trollsas, Philip M. Toleikis

Принадлежит: AngioDevice International GmbH

Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

Подробнее

Номер записи: 3

16-02-2012 дата публикации

Methods and compositions for inhibiting cellular proliferation and surgical adhesion

Номер: US20120040928A1

Автор: Rekha Bansal

Принадлежит: Rekha Bansal

A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammal

Подробнее

Номер записи: 4

08-03-2012 дата публикации

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Номер: US20120059462A1

Автор: Vernon G. Wong

Принадлежит: Allergan Inc

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Подробнее

Номер записи: 5

22-03-2012 дата публикации

Pyrazole oxadiazole derivatives as s1p1 agonists

Номер: US20120071460A1

Автор: Anna Quattropani, Charles Baker-Glenn, Chris KNIGHT, Wesley Blackaby

Принадлежит: MERCK SERONO SA

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R 1 , R 2 and R 3 are as defined in the description.

Подробнее

Номер записи: 6

26-04-2012 дата публикации

Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors

Номер: US20120101086A1

Автор: Christian Alan Paul Smethurst, Emmanuel Hubert Demont, Gail Astra Lorraine Seal, James Matthew Bailey, Jason Witherington, John Alexander Brown, Lee Andrew Harrison

Принадлежит: Glaxo Group Ltd

The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Подробнее

Номер записи: 7

26-04-2012 дата публикации

Compounds

Номер: US20120101123A1

Автор: Chengyong Li, Haibo Zhang, Qinghua Meng, Xichen Lin

Принадлежит: Glaxo Group Ltd

The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

Подробнее

Номер записи: 8

10-05-2012 дата публикации

Swellable biodegradable polymeric matrices and methods

Номер: US20120114589A1

Автор: Emily R. ROLFES-MEYERING, Pamela J. Reed, Stephen Chudzik

Принадлежит: Surmodics Inc

The invention provides biodegradable polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of poly-α(1→4)glucopyranose macromer and a biocompatible biostable hydrophilic macromer. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area, and is able to be degraded at the target site after period of time.

Подробнее

Номер записи: 9

10-05-2012 дата публикации

Surgical compositions for reducing the incidence of adhesions

Номер: US20120115810A1

Автор: Colin Brown

Принадлежит: Individual

A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.

Подробнее

Номер записи: 10

05-07-2012 дата публикации

Omega 3 fatty acid formulations

Номер: US20120172431A1

Автор: Ann Coric, Louis C. Sanfilippo, Seth D. Feuerstein

Принадлежит: CENESTRA LLC

The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof.

Подробнее

Номер записи: 11

02-08-2012 дата публикации

Therapeutic Inhibitor of Vascular Smooth Muscle Cells

Номер: US20120195951A1

Автор: Lawrence L. Kunz, Peter G. Anderson

Принадлежит: Individual

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Подробнее

Номер записи: 12

13-09-2012 дата публикации

Conditioned cell culture medium compositions and methods of use

Номер: US20120230940A1

Автор: Andreas Kern, Anthony Ratcliffe, David L. Horwitz, Gail K. Naughton, Joan Zeltinger, Jonathan N. Mansbridge, Lee K. Landeen, Mark A. Applegate, R. Emmett Pinney

Принадлежит: Skinmedica Inc

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Подробнее

Номер записи: 13

20-09-2012 дата публикации

Treatment of submental fat

Номер: US20120237492A1

Автор: Patricia Walker

Принадлежит: Kythera Biopharmaceuticals LLC

This disclosure relates to compositions, kits and methods for non-surgical reduction of localized subcutaneous fat such as that associated with a cosmetic fat accumulation. The methods employ compositions having specific concentrations of a salt of deoxycholic acid which provides a superior fat cell necrosis with modest adverse effects. Examples of localized subcutaneous fat are found in the submental area, in particular under the chin.

Подробнее

Номер записи: 14

20-09-2012 дата публикации

Antithrombotic dual inhibitors comprising a biotin residue

Номер: US20120238512A1

Автор: Constant Adriaan Anton Van Boeckel, Martin De Kort

Принадлежит: MSD Oss BV

The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (I), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO 2 —R 1 ] [CO—NR 2 —CH(4-benzamidine)-CO—NR 3 R 4 ], wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R 2 and R 3 are independently H or (1-8C)alkyl; R 4 is (-8C)alkyl or (3-8C)cycloalkyl; or R 3 and R 4 together with the nitrogen atom to which they are bonded are a nonaromatic (4-8)membered ring optionally containing another heteroatom, the ring optionally being substituted with (1-8C)alkyl or SO2-(I-8C)alkyl; or a pharmaceutically acceptable salt thereof a prodrug or solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin residue or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombosis or other thrombin-related diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.

Подробнее

Номер записи: 15

20-09-2012 дата публикации

Water-soluble polysaccharide ethers and their use

Номер: US20120238524A1

Автор: Bernd Mueller, Dirk-Henning Menz, Helmut Ritter

Принадлежит: PHARMPUR GMBH

The invention relates to modified polysaccharide ethers having a weight-averaged molecular weight of 40000 to 50000 g/mole, zero shear viscosity of more than 10 Pas, and pseudoplasticity of more than 20, obtainable by reacting cellulose-based polysaccharide ether(s) with at least one mesogenic modification agent or modified polysaccharide ethers, obtainable by reacting polysaccharide ether(s) selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylmethyl cellulose (HEMC), methyl cellulose, and cellulose ethers with methyl and/or ethyl and/or propyl groups and mixtures thereof, with at least one mesogenic modification agent. Said substances can be used to produce gel-like to stable aqueous preparations having viscoelastic flow properties, which are suited for use in the human body, particularly within the scope of ophthalmologic procedures.

Подробнее

Номер записи: 16

04-10-2012 дата публикации

Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors

Номер: US20120252779A1

Автор: Andrew Ratcliffe, Claudio Dagostin, Cyrille Boussard, Kathryn Bell, Nelly Piton, Nigel Ramsden, Richard John Harrison, Sally Oxenford

Принадлежит: Cellzome Ltd

The invention relates to compounds of formula (I) wherein X 1 to X 5 , Y, Z 1 to Z 3 , and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

Подробнее

Номер записи: 17

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells

Номер: US20120276155A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Подробнее

Номер записи: 18

01-11-2012 дата публикации

Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use

Номер: US20120276156A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Подробнее

Номер записи: 19

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Номер: US20120276158A1

Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.

Подробнее

Номер записи: 20

01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers

Номер: US20120276159A1

Автор: Christopher Fraser, Christopher J. ROY, Grayson B. Lipford, Roberto A. MALDONADO

Принадлежит: Selecta Biosciences Inc

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Подробнее

Номер записи: 21

29-11-2012 дата публикации

Anti-adhesion material

Номер: US20120301515A1

Автор: Sumihiro Kamitani, Tomokazu Mukai, Toru Tani

Принадлежит: Kawasumi Laboratories Inc, Shiga University of Medical Science NUC

An object of the present invention is to provide an anti-adhesion material having sufficient in vivo degradability and excellent anti-adhesion characteristics, and also superior to conventional ones in terms of handling properties under wet conditions. The anti-adhesion material ( 1 ) of the present invention has a sheet-like base layer ( 10 ) containing a water soluble polymer (e.g., pullulan), a first cover layer ( 20 ) placed on a surface on one side of the base layer ( 10 ) and containing an aliphatic ester, and a second cover layer ( 30 ) placed on a surface on the other side of the base layer ( 10 ) and containing an aliphatic ester. The optical thickness of each of the first cover layer ( 20 ) and the second cover layer ( 30 ) is set to be 27 nm or greater and smaller than 160 nm.

Подробнее

Номер записи: 22

21-02-2013 дата публикации

Polysaccharide Based Hydrogels

Номер: US20130045182A1

Автор: Glen Gong, Scott Robert Sershen, Suresh Subraya Pai

Принадлежит: Individual

Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

Подробнее

Номер записи: 23

07-03-2013 дата публикации

Transplantable graft-specific induced tolerogenic dendritic cells and methods of use

Номер: US20130058901A1

Автор: Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.

Подробнее

Номер записи: 24

07-03-2013 дата публикации

Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines

Номер: US20130058970A1

Автор: Roberto A. MALDONADO, Takashi Kei Kishimoto

Принадлежит: Selecta Biosciences Inc

Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines.

Подробнее

Номер записи: 25

16-05-2013 дата публикации

Balloon catheter coated with an anti-restenotic active ingredient and a molecular dispersion agent that promotes transport

Номер: US20130123695A1

Автор: Erika Hoffmann, Michael Hoffmann, Roland Horres

Принадлежит: HEMOTEQ AG

The present invention relates to balloon catheters with or without crimped stent, whose surface is coated with at least one antirestenotic agent and at least one transport promoting molecular dispersant, as well as a method for the preparation of these medical devices.

Подробнее

Номер записи: 26

30-05-2013 дата публикации

Methods and compositions for improving implant osseointegration

Номер: US20130138221A1

Автор: Falko Schlottig, Ina Kramer, Michaela Kneissel, Uwe Junker

Принадлежит: NOVARTIS AG

The disclosed methods, uses and articles are in the field of orthopedic and dental implants. In particular, the disclosure relates to compositions and methods for improving the osseointegration of such implants.

Подробнее

Номер записи: 27

18-07-2013 дата публикации

Antibodies that bind to OX40 and their uses

Номер: US20130183315A1

Автор: Antoine Attinger, Jonathan Albert Back, Rami Lissilaa, Samuel Hou, Stanislas Blein

Принадлежит: Glenmark Pharmaceuticals SA

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Подробнее

Номер записи: 28

29-08-2013 дата публикации

Bioactive Scaffold for Therapeutic and Adhesion Prevention Applications

Номер: US20130226313A1

Автор: Brendan Harley, Eric Aiazian, Eric Soller

Принадлежит: Axle International Ltd

A device for inhibiting adhesion of apposing human body tissue layers includes a scaffold having a designated mean pore size, relative density, and degradation half-life. The scaffold may be operably positioned between apposing tissue layers, such as proximate adhesiogenic layers at a wound site, so as to permit remesothelialization of the tissue without formation of fibrous adhesions. The scaffold device of the invention inhibits adhesion formation by promoting contractile cell migration away from the wound site for a predetermined period of time. The invention further relates to device and methods for promoting internal tissue regeneration, and for provision and/or dispensation of therapeutic and/or diagnostic agents in vivo.

Подробнее

Номер записи: 29

12-09-2013 дата публикации

Compositions and methods for increasing vascularization

Номер: US20130237477A1

Автор: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat

Принадлежит: BIOGEN IDEC MA INC, Institut National de la Sante et de la Recherche Medicale INSERM

Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.

Подробнее

Номер записи: 30

10-10-2013 дата публикации

Albumin Fusion Proteins

Номер: US20130266553A1

Автор: Andrew J. Turner, Christopher P. Prior, Darrell Sleep, David J. Ballance, Homayoun Sadeghi

Принадлежит: Human Genome Sciences Inc, Novozymes Biopharma DK AS

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Подробнее

Номер записи: 31

17-10-2013 дата публикации

Method for Reducing or Preventing Transplant Rejection in the Eye and Intraocular Implants for Use Therefor

Номер: US20130274689A1

Автор: Vernon G. Wong

Принадлежит: Allergan Inc

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Подробнее

Номер записи: 32

07-11-2013 дата публикации

Radiopaque Embolic Particles

Номер: US20130295020A1

Автор: Daniel Boyd, Robert J. Abraham, Sharon KEHOE

Принадлежит: DALHOUSIE UNIVERSITY

A radiopaque particulate material one or more of SiO 2 , TiO 2 , La 2 O 3 , Na 2 O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.

Подробнее

Номер записи: 33

14-11-2013 дата публикации

Pharmacological vitreolysis

Номер: US20130302304A1

Автор: Marc De Smet, Steve Pakola

Принадлежит: THROMBOGENICS NV

A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

Подробнее

Номер записи: 34

26-12-2013 дата публикации

Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting parp

Номер: US20130345225A1

Автор: Greg Delahanty, Jie Zhang, Weizheng Xu

Принадлежит: Eisai Inc

The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.

Подробнее

Номер записи: 35

09-01-2014 дата публикации

Organ arrest, protection, preservation and recovery

Номер: US20140011181A1

Автор: Geoffrey P. Dobson

Принадлежит: Hibernation Therapeutics Ltd

The present invention relates to a composition for controlling viability of a tissue including a potassium channel opener or adenosine receptor agonist, a compound for inducing local anaesthesia and compound for reducing the uptake of water by a cell in the tissue. The present invention also relates to the use of the composition according to the invention for controlling viability of a tissue.

Подробнее

Номер записи: 36

20-02-2014 дата публикации

Oil-Based Foamable Carriers And Formulations

Номер: US20140050673A1

Автор: David Schuz, Dov Tamarkin, Elana Gazal, Yohan Hazot

Принадлежит: Foamix Ltd

A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.

Подробнее

Номер записи: 37

20-02-2014 дата публикации

Pharmaceutical compositions

Номер: US20140051671A1

Автор: James N. Chang, John T. Trogden, Robert T. Lyons, Scott Whitcup

Принадлежит: Allergan Inc

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Подробнее

Номер записи: 38

27-02-2014 дата публикации

Viral inactivated platelet extract, use and preparation thereof

Номер: US20140056989A1

Автор: Israel Nur, Lior Weissman, Nina Raver-Shapira, Oleg Belyaev

Принадлежит: Omrix Biopharmaceuticals Ltd

The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

Подробнее

Номер записи: 39

27-03-2014 дата публикации

Anti-il-12/il-23 antibodies

Номер: US20140086922A1

Автор: Adam William Clarke, Andrew James Pow, Anthony Gerard Doyle, Bernadette Wai, George Kopsidas, Lynn Dorothy Poulton, Philip Anthony Jennings

Принадлежит: CEPHALON AUSTRALIA PTY LTD.

Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1.

Подробнее

Номер записи: 40

27-03-2014 дата публикации

Methods of wound care and treatment

Номер: US20140086963A1

Автор: Anthony B. Wood, Gregory J. Archambeau, Richard L. Watson

Принадлежит: Microdiffusion Inc

Particular embodiments disclosed herein relate to gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for wound care related conditions and/or diseases. In certain embodiments, the gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids in order to treat a cosmetic and/or therapeutic symptom of wound care and/or increase proper wound healing.

Подробнее

Номер записи: 41

10-04-2014 дата публикации

Prevention of kidney injury disease

Номер: US20140100162A1

Автор: Ib Bo Lumholtz, Mark T. Houser, Michael Beckert, Samina Khan, Soren Nielsen, Thomas Beaver, Thomas Engelbrecht Nordkild Jonassen

Принадлежит: AbbVie Inc

The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease.

Подробнее

Номер записи: 42

13-01-2022 дата публикации

THERAPEUTIC APPROACHES FOR TISSUE RECONSTRUCTION AND WOUND HEALING TREATMENT

Номер: US20220008518A1

Автор: Chen Di, Liu Yang, Sullivan David A.

Принадлежит:

Disclosed are compositions containing a therapeutically effective amount of free recombinant or synthetic lubricin, a lubricin-supplemented preserved AM, or a lubricin-supplemented non-AM substrate for promoting tissue reconstruction and wound healing in a subject and the methods of using thereof. Lubricin-supplemented preserved amniotic membranes and lubricin-supplemented non-AM substrates, and methods of preparing thereof are also described. 1. A pharmaceutical composition for treating tissue reconstruction and wound healing in a subject , comprising a therapeutically effective amount of a lubricin-supplemented preserved amniotic membrane (AM) or a lubricin-supplemented non-AM substrate.2. The pharmaceutical composition of claim 1 , wherein said preserved AM comprises a cryopreserved AM (CP-AM) or a freeze dried AM (FD-AM).3. The pharmaceutical composition of claim 1 , wherein said lubricin-supplemented preserved AM is a FD-AM soaked in claim 1 , rehydrated with claim 1 , or incubated with lubricin.4. The pharmaceutical composition of claim 1 , wherein said lubricin-supplemented non-AM substrate is a non-AM substrate soaked in claim 1 , rehydrated with claim 1 , or incubated with lubricin.5. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition promotes tissue reconstruction claim 1 , prevents adhesion formation claim 1 , alleviates obstructions claim 1 , facilitates wound healing or performs any combinations thereof.6. The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition promotes tissue reconstruction of an ocular surface claim 5 , an oral surface claim 5 , a periodontal surface claim 5 , an abdominal surface claim 5 , a vaginal surface claim 5 , a cervical surface claim 5 , a uterine surface claim 5 , a skin surface or a mucosal surface.7. The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition prevents adhesion formation of an ocular surface claim 5 , nasolacrimal duct ...

Подробнее

Номер записи: 43

11-01-2018 дата публикации

Composition comprising chitosan for use in the prevention and/or in the treatment of incontinence and/or impotence in a subject undergoing prostatectomy

Номер: US20180008625A1

Автор: Francesco PORPIGLIA, Stefano GEUNA, Thomas Freier

Принадлежит: Individual

Composition comprising chitosan for use in the prevention and/or treatment of incontinence and/or impotence in a subject undergoing prostatectomy.

Подробнее

Номер записи: 44

03-02-2022 дата публикации

Organic compounds

Номер: US20220031609A1

Автор: Alan Edward Royce, Colleen Ruegger, Madhusudhan Pudipeddi, Masaki Sasaki, Tokuhiro Tamura, Tomoyuki Oomura

Принадлежит: Mitsubishi Tanabe Pharma Corp, NOVARTIS AG

A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.

Подробнее

Номер записи: 45

15-01-2015 дата публикации

Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof

Номер: US20150017155A1

Автор: Christopher D. Benjamin, Ellen A. Garber, Frederick R. Taylor, Linda C. Burkly

Принадлежит: BIOGEN IDEC MA INC

The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the C H2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.

Подробнее

Номер записи: 46

21-01-2016 дата публикации

Anti-Adhesive Barrier Membrane Using Alginate and Hyaluronic Acid for Biomedical Applications

Номер: US20160015866A1

Автор: Christine E. Schmidt, Sarah Mayes

Принадлежит: University of Texas System

A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Подробнее

Номер записи: 47

18-01-2018 дата публикации

Peptides and compositions for prevention of cell adhesion and methods of using same

Номер: US20180016311A1

Автор: Amir Zlotkin, Hen Kestenboim

Принадлежит: Tel Hashomer Medical Research Infrastructure and Services Ltd

Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: 3), FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7), and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and moss or any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.

Подробнее

Номер записи: 48

16-01-2020 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN MUSCLE

Номер: US20200016104A1

Автор: Chakravarthy Manu, Comb William, Hamill Michael, Tramontin Tony

Принадлежит:

This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof. 1. A method for reducing fat infiltration in muscle comprising administering to a subject at risk of fat infiltration in muscle a composition comprising:a) a leucine amino acid entity, an arginine amino acid entity, and a glutamine amino acid entity;b) a N-acetylcysteine (NAC) entity; andc) an essential amino acid (EAA)-entity chosen from a histidine amino acid-entity, a lysine amino acid-entity, a phenylalanine amino acid-entity, and a threonine amino acid-entity or a combination of two, three, or four of the EAAs.2. The method of claim 1 , wherein the subject at risk of fat infiltration in muscle has a rotator cuff injury.3. The method of claim 2 , wherein administration of the composition precedes a surgery for the rotator cuff injury.4. The method of claim 2 , further comprising determining a level of fat infiltration in shoulder muscle affected by the rotator cuff injury before surgery.5. The method of claim 2 , further comprising determining a level of fat infiltration in shoulder muscle affected by the rotator cuff injury after surgery.6. The method of claim 2 , wherein the subject is an elderly subject.7. The method of claim 1 , wherein the subject at risk of fat infiltration in muscle has chronic back pain (fat infiltration in paraspinal muscles); HIV patients (fat infiltration in locomotor muscles); spinal cord injury; stroke; COPD; end-stage liver disease (ESLD) claim 1 , hepatic encephalopathy claim 1 , variceal bleeding claim 1 , portal hypertension claim 1 , ascites claim 1 , infection risk claim 1 , sepsis claim 1 , all-cause hospitalization claim 1 , all-cause and liver-related ...

Подробнее

Номер записи: 49

16-01-2020 дата публикации

COMPOSITIONS AND METHODS FOR PAIN AMELIORATION VIA MODIFICATION OF GENE EXPRESSION

Номер: US20200017853A1

Автор: Gonzalez Dina, Harris Scott, Hebert Kimberly, Mamet Julien, Manning Donald C., Martin William, Orr Rick

Принадлежит:

The present disclosure relates to oligonucleotide decoys, pharmaceutical compositions thereof, and the use of such to modulate nociceptive signaling and to prevent and/or treat pain. 1. A method for reducing acute pain , and/or preventing chronic pain , in a patient undergoing surgery , comprising:a. administering a single perioperative intrathecal injection of an effective amount of an oligonucleotide decoy, comprising one or more binding sites for EGR1, to a patient in need thereof, wherein the effective amount of the oligonucleotide decoy is from about 330 mg to about 660 mg.2. The method according to claim 1 , wherein the patient is undergoing a lower extremity surgery.3. The method according to claim 1 , wherein the patient is undergoing an upper body surgery.4. The method according to claim 1 , wherein the patient is undergoing a mid-body or abdominal surgery.5. The method according to claim 1 , wherein the patient is undergoing a knee surgery.6. The method according to claim 1 , wherein the patient is undergoing a total knee arthroplasty.713-. (canceled)14. The method according to claim 1 , wherein the oligonucleotide decoy comprises SEQ ID NO. 42.1518-. (canceled)19. The method according to claim 1 , wherein the effective amount of the oligonucleotide decoy is about 330 mg/3 mL.20. (canceled)21. The method according to claim 1 , wherein the effective amount of the oligonucleotide decoy is about 660 mg/6 mL.22. The method according to claim 1 , wherein the patient experiences a statistically significant or clinically effective reduction in pain through at least day 28 post-surgery.2324-. (canceled)25. The method according to claim 1 , wherein the patient experiences a statistically significant or clinically effective reduction in movement-evoked pain from about day 7 post-surgery through at least day 28 post-surgery.26. The method according to claim 1 , wherein the patient experiences a statistically significant or clinically effective reduction in pain at ...

Подробнее

Номер записи: 50

24-01-2019 дата публикации

TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS

Номер: US20190022033A1

Автор: BUCHER Christoph, GERGELY Peter, KATOPODIS Andreas, Smith Philip

Принадлежит:

The present invention relates to a method of accelerating stem cell engraftement in a patient in need of hematopoietic stem cell transplantation. 2. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use in accelerating engraftment of hematopoietic stem cells in a patient who received said hematopoietic stem cells via a transplantation procedure from a donor.3. A method or a compound according to claim 1 , wherein said patient is first subjected to conditioning thereby destroying substantially all the bone marrow of the patient.4. A method or a compound in accordance to claim 3 , wherein said conditioning is a high dose chemotherapy comprising one or more agents selected from fludarabin claim 3 , busulphan claim 3 , methotrexate claim 3 , cyclosporin A and cyclophosphamide.5. A method or a compound in accordance to claim 3 , wherein said conditioning is a total body irradiation (TBI) according to national guidelines.6. A method or a compound in accordance to claim 3 , wherein hematopoietic stem cell transplantation (HSCT) is carried out following to conditioning claim 3 , e.g. immediately after conditioning claim 3 , or 0-1 day after conditioning claim 3 , or 1-8 days claim 3 , or 1-10 days after conditioning.7. A method or a compound in accordance to claim 3 , wherein treatment of the patient with a compound of formula (I) is commenced 5 days before conditioning claim 3 , in particular 3 days before conditioning and especially 1 day before conditioning.9. A method or a compound in accordance to claim 1 , wherein said compound or a pharmaceutically acceptable salt thereof is KRP203 or the hydrochloride salt thereof.10. A method or a compound in accordance to claim 1 , wherein said compound is administered at a daily dose of 1 claim 1 , 2 claim 1 , 3 4 or 5 mg (per patient). The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells or ...

Подробнее

Номер записи: 51

24-01-2019 дата публикации

Conditionally immortalized long-term stem cells and methods of making and using such cells

Номер: US20190024051A1

Автор: Brian Curtis Turner, John C. Cambier, Sara Ann Johnson, Yosef Refaeli

Принадлежит: NATIONAL JEWISH HEALTH, University of Colorado

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

Подробнее

Номер записи: 52

02-02-2017 дата публикации

Methods for performing a coronary artery bypass graft procedure

Номер: US20170028015A1

Автор: D. Travis Wilson, Kenneth Borow

Принадлежит: Stealth Biotherapeutics Corp

The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.

Подробнее

Номер записи: 53

24-04-2014 дата публикации

Injectable Preformed Macroscopic 3-Dimensional Scaffolds for Minimally Invasive Administration

Номер: US20140112990A1

Автор: David Edwards, David J. Mooney, Roger Warren Sands, Sidi A. Bencherif

Принадлежит: Harvard College

The invention provides polymer compositions for cell and drug delivery.

Подробнее

Номер записи: 54

04-02-2016 дата публикации

Compositions for prevention of adhesions and other barrier applications

Номер: US20160030505A1

Автор: Rutledge Ellis-Behnke, Stephen Richard Kelly, Terrence W. Norchi

Принадлежит: Arch Biosurgery Inc

A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

Подробнее

Номер записи: 55

17-02-2022 дата публикации

METHOD OF TREATING OR PREVENTING HERNIA FORMATION

Номер: US20220047370A1

Автор: Cook Michael, Hodgdon Ian, LAU Frank Ho Pak

Принадлежит:

A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue. 1. A method of repairing a hernia in a subject , comprising:obtaining a graft material; andimplanting the graft material in the subject, wherein the graft material is implanted in contact with an opening in the abdominal wall, and wherein the graft material comprises placental tissue and promotes healing of the abdominal wall opening.2. The method of claim 1 , wherein implanting the graft material includes aligning the graft material with the opening in the abdominal wall.3. The method of claim 1 , wherein the opening comprises a surgical incision.4. The method of claim 1 , wherein the opening comprises debrided fascia.5. The method of claim 1 , wherein the graft material promotes healing of the abdominal fascial edges.6. The method of claim 1 , wherein implanting the graft material does not actively affix the graft material to the abdominal wall.7. The method of claim 1 , wherein implanting the graft material comprises anchoring the graft material to the abdominal wall by pressure claim 1 , an adhesive claim 1 , a clip claim 1 , a tack claim 1 , a suture claim 1 , a staple claim 1 , or a screw.8. The method of claim 1 , wherein implanting the graft material comprises implanting the graft material over or ventral to the abdominal wall opening.9. The method of claim 1 , wherein implanting the graft material comprises implanting the graft material under or dorsal to the abdominal wall opening.10. The method of claim 1 , further comprising substantially or completely closing the abdominal wall opening prior to or after implanting the graft material.11. The method of claim 10 , wherein the abdominal wall opening is closed with synthetic mesh or ...

Подробнее

Номер записи: 56

17-02-2022 дата публикации

Method for treating cardiac conditions with placenta-dervived compositions

Номер: US20220047645A1

Автор: Marc Long, Pamela G. Hitscherich, Zain KHALPEY

Принадлежит: MUSCULOSKELETAL TRANSPLANT FOUNDATION

Provided herein are compositions and methods for treating heart disease. In particular, provided herein are constructs, devices, and systems, each comprising one or more placenta-derived compositions, and their use in treating disorders involving aberrant cardiac rhythms and promoting repair of damaged cardiac tissue. The method of treatment comprises applying one or more constructs on the surface of all or a portion of the heart and/or adjacent tissues, during or after surgical heart treatment.

Подробнее

Номер записи: 57

08-02-2018 дата публикации

Topical composition for the treatment of mucosal lesions

Номер: US20180036337A1

Автор: Jaume BOIX VALVERDE, Ramon BARTOLÍ SOLÉ, Vicente María LORENZO-ZÚÑIGA GARCÍA

Принадлежит: Centro de Investigacion Biomedica en Red CIBER, Fundacio Institut dInvestigació en Ciencies de la Salut Germans Trias I Pujol IGTP

Topical composition for the treatment of mucosal lesions It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

Подробнее

Номер записи: 58

11-02-2016 дата публикации

B7-h4 fusion proteins and methods of use thereof

Номер: US20160039905A1

Автор: Joseph R. Podojil, Linda Liu, Shannon Marshall, Solomon Langermann, Stephen D. Miller

Принадлежит: MEDIMMUNE LLC

Fusion proteins containing B7-II4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by Th1, Th1 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

Подробнее

Номер записи: 59

11-02-2016 дата публикации

Methods and compositions for the inhibition of transplant rejection

Номер: US20160039906A1

Автор: Linda Liu, Solomon Langermann

Принадлежит: MEDIMMUNE LLC

Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.

Подробнее

Номер записи: 60

18-02-2021 дата публикации

PROCESS FOR THE PREPARATION AND PURIFICATION OF THE SODIUM SALT OF HYALURONIC ACID

Номер: US20210046103A1

Автор: BORILE Francesco, CORSA Vincenza, PITTARELLO Mara

Принадлежит: FIDIA FARMACEUTICI S.p.A.

The present invention concerns a process for the preparation and purification of the sodium salt of HA from the fermentation broth of or or from rooster combs, the sodium salt of HA obtained and purified with said process and pharmaceutical, cosmetic and nutritional compositions comprising said sodium salt of HA. 1StreptococcusBacillus. A sodium salt of HA having a final intrinsic viscosity (IV) equal to or higher than 29 dl/g , prepared and purified according to a process for the preparation and purification of the sodium salt of HA from the fermentation broth of or or from rooster combs comprising the following steps:B. extraction, comprising the following steps:B1. addition of Celite to a medium containing non-purified HA and complexing HA with Cetyl Pyridinium Chloride (CPC), under stirring for at least 30 minutes and sedimentation for at least further 30 minutes to form a liquid phase and a solid phase;B2. elimination of the liquid phase formed in step B1;B3. solubilization of the HA present in the solid phase in an aqueous solution of NaCl and collection of a first extract as sodium salt of HA, wherein step B3 is performed 1 to 4 times;B4. joining the extracts from step B3;B5. addition of an aromatic resin having a pore radius ranging from 200 to 300 Angstrom to the joined extracts of B4 and leaving under stirring for at least 8 hours to generate a mixture;B6. filtration of the mixture from step B5;C. purification, comprising the following steps:C1. addition of an aqueous solution of NaOH to the filtrate obtained from step B6;C2. neutralization to a pH ranging from 8 to 9;C3. at least one filtration;C4. precipitation and at least one washing of the sodium salt of HA obtained in step C3 with ethanol and a final washing in an organic solvent;C5. drying of the sodium salt of HA;{'i': Streptococcus', 'Bacillus, 'wherein, when the sodium salt of HA is prepared and purified from the fermentation broth of or , the process comprises a previous initial step of ...

Подробнее

Номер записи: 61

25-02-2016 дата публикации

Decellularized Adipose Tissue

Номер: US20160051728A1

Автор: Lauren E. Flynn

Принадлежит: Queens University at Kingston

This invention provides a method for decellularizing adipose tissue, comprising subjecting the adipose tissue to one or more incubations in an enzymatic digestion solution containing one or more enzymes, and one or more solvent extractions, wherein decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional structure is obtained. The invention also provides a decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional architecture, and bioscaffolds, microcarrier beads, and coatings comprising the decellularized adipose tissue.

Подробнее

Номер записи: 62

14-02-2019 дата публикации

METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SURGICAL ADHESIONS

Номер: US20190048077A1

Автор: Fernhoff Nathaniel, Rinkevich Yuval, Sinha Rahul, Tsai Jonathan, Weissman Irving L.

Принадлежит:

Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided. 1. A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions , the method comprising administering to a subject in need of thereof an agent that disrupts adhesion-formation by injured mesothelial cells.2. A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions , the method comprising administering to a subject in need of thereof an agent that disrupts adhesion-formation by depleting granulocyte or inflammatory granulocytes; or inhibiting granulocyte or inflammatory granulocyte recruitment.3. A method of treating a subject to reduce adhesion formation or to reduce already-formed adhesions , the method comprising administering to a subject in need of thereof an agent that disrupts adhesion-formation by promoting one or both of macrophage and inflammatory monocyte recruitment.4. The method of or , wherein the agent results in one or both of neutrophil depletion and prevention of neutrophil recruitment.5. The method of claim 4 , wherein the agent is a polypeptide that binds a granulocyte marker selected from Gr-1 claim 4 , CD66b claim 4 , CD177 claim 4 , CXCR1 claim 4 , VAP1 claim 4 , CXCR2 claim 4 , and CD10.6. The method of any of - claim 4 , wherein the agent is an ...

Подробнее

Номер записи: 63

20-02-2020 дата публикации

RADIOPAQUE POLYMERS WITH ENHANCED RADIOPACITY

Номер: US20200054770A1

Автор: CASTLEBERRY Jeffrey P., GOODRICH Stephen D.

Принадлежит: EndoShape, Inc.

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer, a second repeating unit derived from a crosslinker monomer having more than two poly-merizable groups and a third repeating unit a derived from a crosslinker monomer having two or more polymerizable groups. Devices formed from radiopaque polymer compositions and methods for synthesizing radiopaque polymer compositions are also provided. 2. The crosslinked polymer network of claim 1 , wherein Aris an iodine containing Caryl group with 3 to 5 iodine atoms attached directly to the ring.3. The crosslinked polymer network of claim 1 , wherein Ris a C-Calkylene group.5. The crosslinked polymer network of claim 4 , wherein r is an integer selected from the range of 3 to 8.6. (canceled)8. The crosslinked polymer network of claim 7 , wherein:{'sup': '10', 'Ris O;'}{'sup': 9', '10, 'each Tand each Tare (meth)acrylate; and'}w and v are each independently integers from 1 to 6.11. The crosslinked polymer network of claim 1 , wherein said crosslinked polymer network has greater than or equal to 15 wt % of said first reagent claim 1 , said crosslinked polymer network has less than or equal to 85 wt % of said second reagent claim 1 , said crosslinked polymer network has less than or equal to 85 wt % of said third reagent claim 1 , or a combination thereof.12. (canceled)13. (canceled)14. The crosslinked polymer network of claim 1 , wherein said crosslinked polymer network comprises between 80 to 90 wt % of said first reagent claim 1 , 1 to 10 wt % of said second reagent and 5 to 15 wt % of said third reagent.15. A radiopaque polymer device for medical application claim 1 , said device or a device feature comprising a polymer composition according to claim 1 , optionally comprising a fiber claim 1 , a coil or ...

Подробнее

Номер записи: 64

17-03-2022 дата публикации

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ADHESIONS AND ILUES

Номер: US20220079903A1

Автор: Hallam Thomas, Rodenrys John

Принадлежит:

Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ilcus. 1. A method for treating or preventing adhesions or ileus in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an aqueous pharmaceutical composition comprising tranexamic acid , polyethylene glycol , glucose , and at least one electrolyte.2. The method of claim 1 , wherein the aqueous pharmaceutical composition is administered to the patient prior to a surgical procedure.3. A method for treating or preventing adhesions or ileus in a patient in need thereof comprising orally administering to the patient a therapeutically effective amount of an aqueous pharmaceutical composition prior to a surgical procedure to treat or prevent adhesions or ileus; wherein the aqueous pharmaceutical composition comprises tranexamic acid claim 1 , polyethylene glycol claim 1 , glucose claim 1 , and at least one electrolyte.4. The method of claim 1 , wherein the adhesions are surgical adhesions.5. The method of claim 1 , wherein the adhesions are abdominal adhesions.6. The method of claim 1 , wherein the adhesions are intestinal adhesions.7. The method of claim 1 , wherein the adhesions are peritoneal adhesions.8. The method of claim 1 , wherein the adhesions are intercostal adhesions.9. The method of claim 1 , wherein the adhesions are abdominal adhesions claim 1 , intestinal adhesions claim 1 , peritoneal adhesions claim 1 , or a combination of two or more thereof.10. The method of claim 1 , wherein treating or preventing adhesions comprises:(i) reducing the incidence of adhesions; (ii) reducing the number of adhesions; (iii) reducing the severity of adhesions; (iv) reducing the thickness of adhesions; (v) reducing the size of the adhesions; (vi) preventing the formation of adhesions; or (vii) a combination of two or more of (i), (ii), (iii), (iv), (v), and (vi).11. The method of claim 1 , wherein treating or preventing ...

Подробнее

Номер записи: 65

11-03-2021 дата публикации

Pharmaceutical Composition For Preventing Or Treating Tissue Adhesion Comprising Integrin a2ß1 Inhibitors

Номер: US20210070866A1

Автор: MOON Hong Joo

Принадлежит: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Disclosed herein are a pharmaceutical composition comprising an integrin α2β1 inhibitor as an active ingredient for prevention or treatment of tissue adhesion, a method for screening a material prophylactic of or therapeutic for tissue adhesion, an anti-adhesion composition comprising the pharmaceutical composition for prevention or treatment of tissue adhesion as an active ingredient, and a method for prevention or treatment of tissue adhesion. The present disclosure can be advantageously used for preventing or treating tissue adhesion. 1. A method for prevention or treatment of tissue adhesion , the method comprising a step of administering a pharmaceutical composition comprising an integrin α2β1 inhibitor as an active ingredient to a subject.2. The method of claim 1 , wherein the integrin α2β1 inhibitor is selected from the group consisting of an antibody claim 1 , an aptamer claim 1 , a natural extract claim 1 , and a compound.3. The method of claim 1 , wherein the integrin α2β1 inhibitor is selected from the group consisting of an anti-integrin α2β1 antibody or an antigen-binding fragment thereof claim 1 , BTT 3016 claim 1 , BTT 3033 claim 1 , BTT 3034 claim 1 , and rhodocetin.4. The method of claim 1 , wherein the tissue adhesion is selected from the group consisting of peritoneal adhesion claim 1 , pelvic adhesion claim 1 , pericardial adhesion claim 1 , peritendinous adhesion claim 1 , and peridural adhesion.5. The method of claim 1 , wherein the pharmaceutical composition is in a formulation form selected from the group consisting of a medicine for internal use claim 1 , an injection claim 1 , a gel claim 1 , a film claim 1 , a perfusate claim 1 , a spray liquid claim 1 , an atomizing or vaporizing liquid claim 1 , a foaming aerosol claim 1 , and an infusion.6. A method for screening a material for prevention or treatment of tissue adhesion claim 1 , the method comprising the steps of:(a) co-culturing macrophage-like THP-1 cells with collagen I-expressing ...

Подробнее

Номер записи: 66

17-03-2016 дата публикации

Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof

Номер: US20160074307A1

Автор: Geoffrey C. Gurtner, Jayakumar Rajadas, Kenneth N. Horne

Принадлежит: ALLERGAN INDUSTRIE SAS

The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.

Подробнее

Номер записи: 67

07-03-2019 дата публикации

NIACINAMIDE (NAM) IN ISCHEMIC TISSUE INJURY

Номер: US20190070211A1

Автор: Parikh Samir M.

Принадлежит:

Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist. 1. (canceled)2. A method of treating , or reducing risk of developing , ischemic tissue injury or a chronic condition of the brain , kidney , or heart , in a subject , the method comprising administering to a subject in need thereof a therapeutically effective amount of a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.3. The method of claim 2 , wherein the ischemic tissue injury is acute kidney injury (AKI); ischemic stroke; or myocardial infarction; the chronic condition of the kidney is diabetic kidney disease claim 2 , hypertensive nephropathy claim 2 , FSGS claim 2 , or ischemic nephropathy; the chronic heart disease is left ventricular hypertrophy claim 2 , ischemic cardiomyopathy claim 2 , or non-ischemic cardiomyopathy; or the chronic cerebral disease is multi-infarct dementia claim 2 , Alzheimer's disease claim 2 , or Parkinson's Lewy body dementia.4. The method of claim 3 , wherein the AKI is delayed graft function.5. A method of treating claim 3 , or reducing risk of developing claim 3 , delayed graft function claim 3 , in a subject claim 3 , the method comprising administering to a donor subject or donor organ claim 3 , and/or to the preservation solutions a therapeutically effective amount of a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.6. The method of claim 4 , wherein the organ-graft is a metabolically active transplanted organ claim 4 , comprising kidney claim 4 , heart claim 4 , liver claim 4 , and lungs.7. The method of claim 2 , wherein the NAD/NAM pathway agonist is Nicotinamide adenine dinucleotide (NAD); niacinamide (NAM) itself; nicotinamide mononucleotide (NMN); Nicotinamide riboside (NR); and P7C3 and analogs thereof claim 2 , optionally P7C3-A20.8. The method of claim 2 , wherein the NAD/NAM ...

Подробнее

Номер записи: 68

07-03-2019 дата публикации

Tissue repair material derived from fish skin and manufacturing method thereof

Номер: US20190070224A1

Автор: Horng-Ji Lai, Jui-Min Ho, Kuan-Hao Huang, Min-Chang Huang, Ta-Wei Su, Yu-Chi Lin, Yu-Wei Chang, Yun-Ting HSU

Принадлежит: Body Organ Biomedical Corp

A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

Подробнее

Номер записи: 69

16-03-2017 дата публикации

Polymethylmethacrylate bone cement with adjustable initial viscosity, and method for producing a bone cement dough with variable initial viscosity

Номер: US20170072093A1

Автор: Sebastian Vogt, Thomas Kluge

Принадлежит: HERAEUS MEDICAL GMBH

A polymerizable polymethylmethacrylate bone cement, in which the initial viscosity of the cement dough can be controlled. The polymerizable bone cement composition comprises a monomer for radical polymerization, a powdered polymethylmethacrylate-co-polymer soluble in the monomer or a mixture comprising polymethylmethacrylate-co-polymers, a polymerization initiator, and a radiopaquer, wherein the powdered polymethylmethacrylate-co-polymer comprises at least one particulate polymethylmethacrylate-co-polymer having a molar mass of more than or equal to 200,000 g/mol, and the polymethylmethacrylate-co-polymer is obtainable by polymerization of a mixture of 90.0% or more by weight methylmethacrylate and 10.0% or less by weight of one or more comonomers, wherein the weight ratio of component A comprising the polymethylmethacrylate-co-polymer, radiopaquer, and polymerization initiator, and component B comprising a monomer for radical polymerization, stabiliser, and polymerization accelerator, is approximately 2.0 to 3.4 to 1.0, for controlling the initial viscosity of the bone cement dough formed by mixing components A and B.

Подробнее

Номер записи: 70

05-03-2020 дата публикации

Antibodies That Bind To OX40 and Their Uses

Номер: US20200071409A1

Автор: Antoine Attinger, Jonathan Albert Back, Rami Lissilaa, Samuel Hou, Stanislas Blein

Принадлежит: Ichnos Sciences SA

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Подробнее

Номер записи: 71

23-03-2017 дата публикации

Melatonin and its use in preventing postoperative complications

Номер: US20170079953A1

Автор: Heinz Schneider

Принадлежит: Nutri-Fit & Co KG GmbH

The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions.

Подробнее

Номер записи: 72

31-03-2022 дата публикации

AXITINIB-LOADED NANOFIBER MEMBRANE, PREPARATION METHOD FOR THE SAME, AND ITS USE OF ANTI-ADHESION AFTER A SURGERY

Номер: US20220096717A1

Автор: DAI Zihao, FENG Bei, Liu Yiwei, Wang Xingang, YE Lincai, ZHANG Hao

Принадлежит:

The application discloses a use of nanofiber membrane in the preparation of medical apparatus for anti-adhesion after a surgery, wherein small molecule drug, inhibiting vascular endothelial growth factor and/or inhibiting vascular endothelial growth factor receptor, is loaded into the nanofiber membrane. The nanofiber membrane provided in the present application has the following advantages: it has good biocompatibility, excellent mechanical properties, excellent flexibility and smoothness when exposed to water, good air permeability, and has the ability to effectively prevent adhesion between the heart and surrounding tissues. In addition, it can also be applied to other surgical operations, such as prevention of adhesions in the abdominal cavity, pelvis, and tendons. 1. A use of a nanofiber membrane of small molecule drug in the preparation of medical apparatus for anti-adhesion after a surgery , wherein the small molecule drug , inhibiting vascular endothelial growth factor and/or inhibiting vascular endothelial growth factor receptor , is loaded into the nanofiber membrane.2. The use of claim 1 , wherein the surgery is cardiac surgery.3. The use of claim 2 , wherein the anti-adhesion is to prevent adhesion between the heart to sternum and/or pericardium.4. The use of claim 1 , wherein the small molecule drug is Axitinib.5. The use of claim 4 , wherein the amount of Axitinib loaded in the nanofiber membrane is not less than 1%.6. The use of claim 5 , wherein the amount of Axitinib loaded in the nanofiber membrane is in a range of 2% to 30%.7. The use of claim 1 , wherein the nanofiber membrane is a gelatin/polycaprolactone nanofiber membrane.8. The use of claim 7 , wherein the nanofiber membrane is obtained from a gelatin/polycaprolactone spinning solution containing Axitinib by electrospinning.9. The use of claim 7 , wherein the nanofiber membrane is produced by a method comprising the steps of: preparing a first spinning solution and a second spinning solution ...

Подробнее

Номер записи: 73

31-03-2016 дата публикации

Activated leukocyte conditioned supernatant and uses for wound healing

Номер: US20160089420A1

Автор: Eilat Bain, Irene Ginis, Marina Bubis, Mitchell Shirvan

Принадлежит: Macrocure Ltd

Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

Подробнее

Номер записи: 74

31-03-2016 дата публикации

Compositions and methods for treating post-operative complications of cardiopulmonary surgery

Номер: US20160089423A1

Автор: Dan Abrahamov

Принадлежит: MOR RESEARCH APPLICATIONS LTD

Disclosed herein are compositions and methods for treating damage inflicted by use of a cardio-pulmonary bypass (CPB) machine, particularly excessive bleeding and multi organ failure, by administering a pharmaceutical composition comprising alpha-1 antitrypsin (AAT).

Подробнее

Номер записи: 75

02-04-2015 дата публикации

Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins

Номер: US20150094267A1

Автор: Ashok Malavalli, Gnel MKRTCHYAN, Kim D. Vandegriff

Принадлежит: Individual

The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.

Подробнее

Номер записи: 76

04-04-2019 дата публикации

Method for Treatment and Prevention of Biofilm Formation During Breast Augmentation Procedures

Номер: US20190099259A1

Автор: Albert Rodewald, Jack Fisher, R. Stephen Porter

Принадлежит: Integrated Healing Technologies LLC, Phase One Health LLC

The present disclosure provides methods and compositions for the treatment and prevention of infections and biofilm prevention during breast augmentation procedures. The present disclosure also provides methods and compositions for the prevention of anaplastic large-cell lymphoma following breast augmentation procedures. The present methods comprise providing a breast implant pocket at a surgical site in a patient and irrigating the pocket with a solution of hypochlorous acid. In some embodiments, the methods further comprise treating a breast implant with a solution of hypochlorous acid for a period of time prior to a breast augmentation procedure. Further provided are hypochlorous acid solutions useful in the aforementioned methods.

Подробнее

Номер записи: 77

03-07-2014 дата публикации

METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES

Номер: US20140186368A1

Автор: Joachim Kempeni, Roberta Weiss, Steven A. Fischkoff

Принадлежит: ABBVIE BIOTECHNOLOGY LTD

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

Подробнее

Номер записи: 78

18-04-2019 дата публикации

Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor

Номер: US20190111106A1

Автор: Casandra L. Hoffman, Ph.D., Erik L. HEWLETT

Принадлежит: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Provided are compositions that include an effective amount of a peptide or polypeptide derived from a Bordetella ACT AC domain, optionally wherein the peptide or polypeptide is 80-100% identical to an amino acid sequence as set forth in SEQ ID NOs: 1-5 and 44-53. Also provided are methods of using the same for preventing and/or treating a diseases, disorders, and conditions associated with the presence and/or development of biofilm; and for reducing the incidence of nosocomial infections; for inhibiting biofilm development and/or for reducing or eliminating biofilm present on medical, dental, and industrial surfaces.

Подробнее

Номер записи: 79

17-07-2014 дата публикации

Oxygenated demineralized bone matrix for bone growth

Номер: US20140199409A1

Автор: Andrew J. Carter, Frank M. Phillips, Nelson L. Scarborough, Richard K. Grant, Stephen H. Hochschuler

Принадлежит: TheraCell Inc

An improved composition for inducing bone growth is provided that is a mixture of DBM and a perfluorocarbon oxygen carrier. Injection/implantation of a composition of DBM and a perfluorocarbon results in enhancement of bone formation.

Подробнее

Номер записи: 80

14-05-2015 дата публикации

Polymeric Tissue Sealant

Номер: US20150133579A1

Автор: Annemie Rehor, Simona Cerritelli

Принадлежит: Kuros Biosurgery AG

Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein: i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2 ii) the second precursor molecule is of the general formula: A-[(C 3 H 6 O) n —(C 2 H 4 O) m —B] i wherein m and n are integers from 1 to 200 i is greater than 2 A is a branch point B is a conjugated unsaturated group The precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.

Подробнее

Номер записи: 81

02-05-2019 дата публикации

NEUROTOXIN COMPOSITIONS FOR USE IN IMPROVING LUNG FUNCTION

Номер: US20190125844A1

Автор: Abushakra Sawsan, Ahmad Wajdie, Hasan Fauad

Принадлежит:

Disclosed herein are compositions and methods for use in reducing lung function inhibition. 1. A method for reducing inhibition of lung function , comprising administering a therapeutically effective amount of a fast-acting botulinum neurotoxin to a patient's torso prior to a surgical procedure.2. The method of claim 1 , wherein the administered dose comprises an amount between 2 and 20 nanograms of neurotoxin.3. The method of claim 2 , wherein said administration comprises injection of the neurotoxin.4. The method of claim 3 , wherein said method further comprises administration of an opioid to the patient.5. The method of claim 3 , wherein said method further comprises administration of an intermediate-acting neurotoxin to the patient.6. The method of claim 3 , wherein said method further comprises administration of a long-acting neurotoxin to the patient.7. The method of claim 3 , wherein said administration comprises multiple injections of a composition comprising said neurotoxin claim 3 , and the total neurotoxin dose is 1 to 15 nanograms of said neurotoxin.8. The method of claim 7 , wherein at least the pectoralis muscle is injected.9. The method of claim 7 , wherein at least the serratus anterior muscle is injected.10. The method of claim 7 , wherein at least the deltoid muscle is injected. This application claims the benefit of U.S. Provisional Application No. 62/580,660 filed on Nov. 2, 2017, the entire content of which is incorporated herein by reference.The present specification relates to the use of neurotoxins to reduce muscle and nerve activity in the vicinity of the lungs.Surgical procedures can be very invasive, particularly those involving the torso. Recovery can be complicated by inflammation and pain, as well as reduced lung function caused by muscle and nerve activity.Disclosed herein are compositions and methods comprising neurotoxins and the use thereof to improve, maintain, or lessen the reduction of lung function, for example following a ...

Подробнее

Номер записи: 82

19-05-2016 дата публикации

Cd34 stem cell-related methods and compositions

Номер: US20160136207A1

Автор: Manfred J. Stangl, Matthias C. Raggi, Peter J. Nelson, Ralf Huss

Принадлежит: Apceth GmbH and Co KG

This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34 stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34 stem cells used in the instant methods can be genetically, modified or not, depending on the disorder treated.

Подробнее

Номер записи: 83

17-05-2018 дата публикации

Immobilized plasminogenase composition, preparation process, use and device comprising such a composition

Номер: US20180135038A1

Автор: Carine SAUX, Francoise Ouarne, Gerard Reboul

Принадлежит: Arcadophta

Disclosed is an enzymatic composition including:—at least one enzyme, termed plasminogenase, for converting, into plasmin, plasminogen from a blood plasma medium including plasminogen;—a solid support that is insoluble in aqueous solution, the solid support having dimensions suitable for being able to be retained on a filter having a cut-off threshold of less than or equal to 0.22 μm. The plasminogenase is bound to the solid support and remains bound to this support on contact with a blood plasma medium. The composition is in the dry state. Also disclosed is a process for preparing such an enzymatic composition, to the use thereof and to a device ( 20 ) for preparing a blood plasma medium ex vivo rich in sterile plasmin and free of enzymatic composition.

Подробнее

Номер записи: 84

10-06-2021 дата публикации

Chemoembolization agents

Номер: US20210169801A1

Автор: David IMAGAWA, Fabio Tucci, Graham Beaton, James NA, Satheesh RAVULA

Принадлежит: Bruin Biosciences Inc, UNIVERSITY OF CALIFORNIA

A chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug.

Подробнее

Номер записи: 85

17-06-2021 дата публикации

COMPOSITION CONTAINING CHLORINE DIOXIDE AND METHODS FOR USING SAME

Номер: US20210177890A1

Автор: PAMEL Gregory J.

Принадлежит:

The present invention relates to a composition comprising chlorine dioxide useful in the treatment of active infections of the eye, as well as prophylaxis and treatment of such infections. The invention also relates to uses of compositions including effective amounts of chlorine dioxide in the eye to obtain benefit without detrimentally affecting the eye. 1. An ophthalmic composition comprising an effective amount of chlorine dioxide , about 0.01% (w/w) to about 2% (w/w) dextrin or cyclodextrin , and an aqueous medium.2. The composition of claim 1 , wherein the chlorine dioxide is chlorine dioxide containing complexes selected from the group consisting of complexes of chlorine dioxide with carbonate claim 1 , complexes of chlorine dioxide with bicarbonate claim 1 , stabilized oxychloro complex (SOC) claim 1 , and combinations thereof.3. The composition of claim 1 , wherein the chlorine dioxide comprises about 0.005% (w/w) to about 10% (w/w) of the total composition.4. The composition of claim 1 , further comprising nanoparticles or microparticles selected from the group consisting of hybrid polyamidoamine (PAMAM) dendrimer hydrogel/poly (lactic-co-glycolic acid) (PLGA) nanoparticles or microparticles (HDNP); chitosan (CS) nanoparticles or microparticles; thiolated chitosan nanoparticles or microparticles; calcium phosphate (CaP) nanoparticles or microparticles; poly (lactic-co-glycolic acid) copolymer (PLGA) nanoparticles or microparticles; poly (ethyleneglycol)-block-poly(caprolactone) nanoparticles or microparticles; core/shell nanoparticles or microparticles composed of a lecithin liposome core; PEG-block-PPG diacrylate copolymer (DA-PF 127) nanoparticles and microparticles; inorganically-coated retinoic acid (atRA) nanoparticles or microparticles; poly (lactic acid) (PLA) homopolymers and PEG-block-PLA copolymer nanoparticles or microparticles; PEG-block-PPG copolymer nanoparticles and microparticles; PEGylated liposome-protamine-hyaluronic acid nanoparticles or ...

Подробнее

Номер записи: 86

16-05-2019 дата публикации

Chemical Compounds

Номер: US20190144384A1

Автор: AXTEN Jeffrey Michael, Cheung Mui, DEAN Anthony William, DeMartino Michael P., Eidam Hilary Schenck, KALITA Biswajit, Kethiri Raghava Reddy, KRISTAM Rajendra

Принадлежит:

The invention is directed to substituted pyrrolidine derivatives. Specifically, the invention is directed to compounds according to Formula III: 4. A pharmaceutical composition comprising a compound according to or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.5. A method of treating a disease selected from: cancer claim 1 , pre-cancerous syndromes claim 1 , Alzheimer's disease claim 1 , spinal cord injury claim 1 , traumatic brain injury claim 1 , ischemic stroke claim 1 , stroke claim 1 , diabetes claim 1 , Parkinson disease claim 1 , Huntington's disease claim 1 , Creutzfeldt-Jakob Disease claim 1 , and related prion diseases claim 1 , progressive supranuclear palsy claim 1 , amyotrophic lateral sclerosis claim 1 , myocardial infarction claim 1 , cardiovascular disease claim 1 , inflammation claim 1 , fibrosis claim 1 , chronic and acute diseases of the liver claim 1 , chronic and amuicute diseases of the lung claim 1 , chronic and acute diseases of the kidney claim 1 , chronic traumatic encephalopathy (CTE) claim 1 , neurodegeneration claim 1 , dementia claim 1 , cognitive impairment claim 1 , atherosclerosis claim 1 , ocular diseases claim 1 , in organ transplantation and arrhythmias claim 1 , in a mammal in need thereof claim 1 , which comprises administering to such mammal a therapeutically effective amount of a compound as described in or a pharmaceutically acceptable salt thereof.6. The method of wherein the mammal is a human.78-. (canceled)9. The method according to wherein said cancer is selected from: brain (gliomas) claim 5 , glioblastomas claim 5 , astrocytomas claim 5 , glioblastoma multiforme claim 5 , Bannayan-Zonana syndrome claim 5 , Cowden disease claim 5 , Lhermitte-Duclos disease claim 5 , breast claim 5 , colon claim 5 , head and neck claim 5 , kidney claim 5 , lung claim 5 , liver claim 5 , melanoma claim 5 , ovarian claim 5 , pancreatic claim 5 , adenocarcinoma claim 5 , ductal adenocarcinoma claim 5 ...

Подробнее

Номер записи: 87

21-08-2014 дата публикации

Ophthalmologic Irrigation Solutions and Method

Номер: US20140235597A1

Автор: Gregory A. Demopulos, Jeffrey M. Herz, Pamela Pierce Palmer

Принадлежит: Omeros Medical Systems Inc

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

Подробнее

Номер записи: 88

08-06-2017 дата публикации

Dissolvable nasal sinus sponge

Номер: US20170157283A1

Автор: Denise E. Guenther, Ethan G. Sherman, Wei Chen

Принадлежит: Medtronic Xomed LLC

An implantable article comprising a dissolvable sponge derived from the mixture of chitosan, a first polysaccharide and a second polysaccharides. The polysaccharides have different number average molecular weight characteristics to enable the control of the mechanical features of the sponge.

Подробнее

Номер записи: 89

24-06-2021 дата публикации

NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND

Номер: US20210188837A1

Автор: ISHIGURO Noriko, OMORI Osamu, SHIKANAI Daisuke

Принадлежит: ASAHI KASEI PHARMA CORPORATION

A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EPreceptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like. 2. The compound or a salt thereof according to claim 1 , wherein Ris —H claim 1 , —Cl claim 1 , or —Br.8. The compound or a salt thereof according to claim 7 , wherein Ris —H.9. The compound or a salt thereof according to claim 7 , wherein Ris —Cl.10. The compound or a salt thereof according to claim 7 , wherein Ris —Br.14. A pharmaceutical composition containing the compound according to claim 1 , or a pharmaceutically acceptable salt thereof as an active ingredient claim 1 , and a pharmaceutically acceptable carrier.15. A method for therapeutic treatment and/or promotion of healing of fracture claim 14 , which comprises administering to a patient in need thereof a pharmaceutical composition according to .16. A method for promotion of bone union in spinal fusion surgeries claim 14 , which comprises administering to a patient in need thereof a pharmaceutical composition according to .17. A pharmaceutical composition containing the compound according to claim 12 , or a pharmaceutically acceptable salt thereof as an active ingredient claim 12 , and a pharmaceutically acceptable carrier.18. A method for therapeutic treatment and/or promotion of healing of fracture claim 17 , which comprises administering to a patient in need thereof a pharmaceutical composition according to .19. A method for promotion of bone union in spinal fusion surgeries claim 17 , which comprises administering to a patient in need thereof a pharmaceutical composition according to . This application is a Continuation of copending application Ser. No. 16/333,510, filed on Mar. 14, 2019, which is the National Phase under 35 U.S.C. § 371 of International ...

Подробнее

Номер записи: 90

25-06-2015 дата публикации

One component fibrin glue comprising zymogens

Номер: US20150174215A1

Автор: Anne Gorman, Ashley Deanglis, Israel Nur, SIVAN DORON, Yair Pilpel, Yuri ZHERDEV

Принадлежит: Ethicon Inc, Omrix Biopharmaceuticals Ltd

Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX).

Подробнее

Номер записи: 91

29-09-2022 дата публикации

Neurotoxins for use in inhibiting cgrp

Номер: US20220306704A1

Автор: Fauad HASAN, Michael Jarpe

Принадлежит: Bonti Inc

Disclosed herein are compositions and methods for use in inhibiting CGRP production and release.

Подробнее

Номер записи: 92

25-06-2015 дата публикации

Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse

Номер: US20150175680A1

Автор: John R. Schreiber, Kulwant Kamboj KAUR

Принадлежит: CASE WESTERN RESERVE UNIVERSITY

The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomanas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Подробнее

Номер записи: 93

01-07-2021 дата публикации

Hypotensive lipid-containing biodegradable intraocular implants and related methods

Номер: US20210196729A1

Автор: Patrick M. Hughes

Принадлежит: Allergan Inc

Biocompatibie intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Подробнее

Номер записи: 94

11-09-2014 дата публикации

Tissue scaffolds derived from forestomach extracellular matrix

Номер: US20140257482A1

Автор: Barnaby Charles Hough May, Brian Roderick Ward, Keryn Dallas JOHNSON

Принадлежит: Mesynthes Ltd

The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.

Подробнее

Номер записи: 95

18-09-2014 дата публикации

Tinted antiseptic solutions having improved stability

Номер: US20140261454A1

Автор: James Bardwell, Kenneth M. DOKKEN, Tenoch Benitez

Принадлежит: CareFusion 2200 Inc

An antiseptic solution including, a cationic antiseptic agent, a film forming polymer, an anionic tinting agent, and a solvent, wherein the cationic antiseptic agent, the film forming polymer and the anionic tinting agent each remain solubilized within the solution for greater than about 1 hour at 25° C. and 60% relative humidity. The antiseptic agent is preferably octenidine dihydrochloride or chlorhexadine gluconate. The film forming polymer is preferably an acrylate polymer. The solvent is preferably ethanol, isopropanol, and n-propanol. When a drape is adhered to a dried surgical film via the antiseptic solution, the force required to peel the drape from the surgical film is at least about 105 g/25 mm.

Подробнее

Номер записи: 96

04-06-2020 дата публикации

COMPOSITIONS AND METHODS FOR REDUCING MUSCLE CONTRACTION

Номер: US20200171010A1

Автор: Bright Jessica Catherine, Burback Brian L., Johnson Jerry D.

Принадлежит:

Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically acceptable salt thereof to a subject in need thereof in an amount sufficient to achieve said reduced muscle contraction/neuromuscular blockade. Kits and articles of manufacture comprising a container having a label and a composition are also disclosed. 114-. (canceled)15. A method of inducing neuromuscular blockade via modulation of a nicotinic receptor in an individual in need thereof , comprising administering an oxime or pharmaceutically acceptable salt thereof , an analgesic , and an anesthetic to said individual , wherein said oxime or pharmaceutically acceptable salt thereof is administered in an amount that achieves cessation of a muscle contraction , wherein said muscle is skeletal muscle.16. The method of claim 15 , wherein said oxime is selective for diaphragm muscle.17. The method of claim 15 , wherein said oxime is selective for peripheral skeletal muscle.18. The method of claim 15 , wherein said oxime is selective for both diaphragm muscle and or peripheral skeletal muscle.20. The method of claim 15 , wherein said oxime is MMB4 or a pharmaceutically acceptable salt thereof21. The method of claim 15 , wherein said pharmaceutically acceptable salt thereof is selected from dichloride or dimethane sulfonate.22. The method of claim 15 , wherein said oxime is administered prior to or during a surgical procedure.23. The method of claim 15 , wherein said oxime is administered via a route selected from intravenously claim 15 , parenterally claim 15 , intramuscularly claim 15 , or a combination thereof.24. The method of claim 15 , wherein said oxime administered as a composition comprising from about 25 to about 500 mg/mL claim 15 , or from about 50 to about 250 mg/mL or about 100 mg/mL oxime in a pharmaceutically acceptable carrier ...

Подробнее

Номер записи: 97

04-06-2020 дата публикации

TOPICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL LESIONS

Номер: US20200171073A1

Автор: BARTOLÍ SOLÉ Ramon, BOIX VALVERDE Jaume, LORENZO-ZÚÑIGA GARCÍA Vicente María

Принадлежит:

It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract. 1. A topical composition comprising:a) from 0.6 to 1.5 wt % of a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof,b) from 0.75 to 25 wt % of one or more adhesive agents, andc) from 1.5 to 2.5 wt % of a non-absorbable antibiotic;wherein all percentages are expressed with respect to the total weight of the composition, provided that the sum of the amounts of the components is equal to or less than 100%.2. The topical composition according to claim 1 , having an adhesion at body temperature which is equal to or lower than −10 mN/s.3. The topical composition according to claim 1 , having a viscosity at body temperature which is from 0.5 to 1600 Pa·s.4. The topical composition according to claim 1 , which is an aqueous composition.5. The topical composition according to claim 1 , wherein the hyaluronic acid or a pharmaceutically or veterinary acceptable salt is hyaluronic acid sodium salt.6. The topical composition according to claim 5 , wherein the adhesive agent is a cellulose ether claim 5 , and the non-absorbable antibiotic is rifaximin.7. The topical composition according to claim 6 , which is an aqueous composition.8. The topical composition according to claim 6 , which comprises a pluronic compound.9. An injection device comprising the topical composition as defined in .10. A kit comprising the injection device as defined in claim 9 , and a delivery device suitable to be ...

Подробнее

Номер записи: 98

15-07-2021 дата публикации

Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

Номер: US20210212961A1

Автор: Andrea Small-Howard, Helen TURNER

Принадлежит: GBS Global Biopharma Inc

Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

Подробнее

Номер записи: 99

16-07-2015 дата публикации

Humanized anti-beta7 antagonists and uses therefor

Номер: US20150197560A1

Автор: Mark S. Dennis, Sherman Fong

Принадлежит: Genentech Inc

The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.

Подробнее

Номер записи: 100

Настройки

Небесная энциклопедия

Мониторинг СМИ

Форма поиска